Literature DB >> 11958311

High or low hematocrits during cardiopulmonary bypass for patients undergoing coronary artery bypass graft surgery? An evidence-based approach to the question.

Robert C Groom1.   

Abstract

We have observed an inverse relationship between a CPB Hct <20% and the need for cardiac support and hospital mortality. These data call for an aggressive and concerted effort to avoid a CPB Hct of <20%. The focus should be directed at women and small men since this subset of patients are most likely to experience low CPB Hct. A comprehensive, multimodality blood-conservation plan that involves the use of erythropoietin, aprotinin, preoperative autologous donation, shed blood reinfusion, and minimal phlebotomy for blood testing was proposed by Rosengart and colleagues based on their experience in caring for 50 Jehovah's Witness patients. Efforts to conserve blood and ensure hemostasis should cover the entire spectrum of care, including preoperative phlebotomy (for blood tests), diagnostic and interventional procedures, and intraoperative and postoperative care. Further work is needed to understand the mechanism for the relationship between low Hct and adverse outcomes. Each open-heart center should consider the Hct question carefully, examining both the published literature and their own results related to CPB Hct and patient outcomes.

Entities:  

Mesh:

Year:  2002        PMID: 11958311     DOI: 10.1191/0267659102pf548oa

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  2 in total

1.  Influence of intraoperative fluid volume on cardiopulmonary bypass hematocrit and blood transfusions in coronary artery bypass surgery.

Authors:  Jeffrey A Campbell; David W Holt; Valerie K Shostrom; Samuel J Durham
Journal:  J Extra Corpor Technol       Date:  2008-06

2.  Significantly increased low shear rate viscosity, blood elastic modulus, and RBC aggregation in adults following cardiac surgery.

Authors:  Yi-Fan Wu; Po-Shun Hsu; Chien-Sung Tsai; Pin-Cheng Pan; Yeng-Long Chen
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.